Illustrative image: scientists working in a laboratory Illustrative image

Advancing innovative solutions for severe rare diseases

A clinical-stage biotechnology company with two investigational programs: SCY-770 for ADPKD and SCY-247, an antifungal now supported by a BARDA contract.

$214M

Potential BARDA funding if all options are exercised

2029

Expected cash runway

Illustrative image: scientist using a microscope
Illustrative image

Lead program · SCY-770

A direct AMPK activator for ADPKD

  • An investigational, oral therapy in development for autosomal dominant polycystic kidney disease (ADPKD), a progressive genetic kidney disorder.
    • About 140,000 diagnosed U.S. patients
    • FDA Orphan Drug Designation
    • Phase 2 proof-of-concept planned to start in Q4 2026
Illustrative image: scientist pipetting in a laboratory
Illustrative image

Fungerps: our anti-fungal platform

SCY-247, our second-generation fungerp

  • An investigational oral and IV antifungal for invasive candidiasis and prevention of invasive fungal infections.
    • Orphan, QIDP and Fast Track designations
    • IV Phase 1 dosing complete; analysis ongoing
    • BARDA: up to ~$214M if all options are exercised

Two programs moving toward Phase 2

Cash is expected to fund operations into 2029. The BARDA contract is not expected to change SCY-770 plans or that runway.

$71.1M

Cash & investments, 6/30/26

~$18.5M

BARDA initial base period

Q4 2026

SCY-770 Phase 2 planned

SCYNEXIS, Inc. NASDAQ: SCYX
Investors

Forward-looking statements on BARDA options, trial timing and cash runway. SCY-770 and SCY-247 are investigational, not FDA-approved. See SEC filings.